Brain "ouabain" and angiotensin II contribute to cardiac dysfunction after myocardial infarction

被引:45
作者
Leenen, FHH [1 ]
Yuan, BX [1 ]
Huang, BS [1 ]
机构
[1] Univ Ottawa, Inst Heart, Hypertens Unit, Ottawa, ON K1Y 4W7, Canada
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 1999年 / 277卷 / 05期
关键词
heart; heart failure; left ventricle dilation; ouabain; renin-angiotensin system;
D O I
10.1152/ajpheart.1999.277.5.H1786
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In chronic heart failure (CHF), sympathetic activity increases in parallel with the impairment of left ventricle (LV) function, and sympathetic hyperactivity has been postulated to contribute to the progression of heart failure. In the brain, compounds with ouabain-like activity ("ouabain," for brevity) and the renin-angiotensin system contribute to sympathetic hyperactivity in rats with CHF after myocardial infarction (MI). In the present studies, we assessed whether, in rats, chronic blockade of brain "ouabain" or the brain renin-angiotensin system inhibits the post-MI LV dysfunction. In rats, an MI was induced by acute coronary artery ligation. At either 0.5 or 4 wk post-MI, chronic treatment with Fab fragments for blocking brain "ouabain" or with losartan for blocking brain AT(1) receptors was started and continued until 8 wk post-MI using osmotic minipumps connected to intracerebroventricular cannulas. At 8 wk post-MI, in conscious rats, LV pressures were measured at rest and in response to volume and pressure overload, followed by LV passive pressure-volume curves in vitro. At 8 wk post-MI, control MI rats exhibited clear increases in LV end-diastolic pressure (LVEDP) at rest and in response to pressure and volume overload. LV pressure-volume curves in vitro showed a marked shift to the right. Intravenous administration of the Fab fragments or losartan at rates used for central blockade did not affect these parameters. In contrast, chronic central blockade with either Fab fragments or losartan significantly lowered LVEDP at rest (only in 0.5- to 8-wk groups) and particularly in response to pressure or volume overload. LV dilation, as assessed from LV pressure-volume curves, was also significantly inhibited. These results indicate that chronic blockade of brain "ouabain" or brain AT(1) receptors substantially inhibits development of LV dilation and dysfunction in rats post-MI.
引用
收藏
页码:H1786 / H1792
页数:7
相关论文
共 25 条
[1]  
BUTLER VP, 1977, FED PROC, V36, P2235
[2]   HETEROGENEITY OF VENTRICULAR REMODELING AFTER ACUTE MYOCARDIAL-INFARCTION IN RATS [J].
CAPASSO, JM ;
LI, P ;
ZHANG, X ;
ANVERSA, P .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (02) :H486-H495
[3]  
COHN JN, 1989, AM J HYPERTENS, V2, pS353
[4]   REFLEX REGULATION OF RENAL NERVE ACTIVITY IN CARDIAC-FAILURE [J].
DIBONA, GF ;
SAWIN, LL .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :R27-R39
[5]   ANG-II RECEPTOR BLOCKADE AND ARTERIAL BAROREFLEX REGULATION OF RENAL NERVE ACTIVITY IN CARDIAC-FAILURE [J].
DIBONA, GF ;
JONES, SY ;
BROOKS, VL .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1995, 269 (05) :R1189-R1196
[6]   LEFT-VENTRICULAR DIASTOLIC PRESSURE-VOLUME RELATIONS IN RATS WITH HEALED MYOCARDIAL-INFARCTION - EFFECTS ON SYSTOLIC FUNCTION [J].
FLETCHER, PJ ;
PFEFFER, JM ;
PFEFFER, MA ;
BRAUNWALD, E .
CIRCULATION RESEARCH, 1981, 49 (03) :618-626
[7]   Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials [J].
Heidenreich, PA ;
Lee, TT ;
Massie, BM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (01) :27-34
[8]   Blockade of brain ''ouabain'' prevents the impairment of baroreflexes in rats after myocardial infarction [J].
Huang, BS ;
Yuan, BX ;
Leenen, FHH .
CIRCULATION, 1997, 96 (05) :1654-1659
[9]   BRAIN OUABAIN-LIKE ACTIVITY AND THE SYMPATHOEXCITATORY AND PRESSOR EFFECTS OF CENTRAL SODIUM IN RATS [J].
HUANG, BS ;
HARMSEN, E ;
YU, HL ;
LEENEN, FHH .
CIRCULATION RESEARCH, 1992, 71 (05) :1059-1066
[10]   beta-adrenoceptor blockers in chronic heart failure - a review [J].
Krum, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) :111-118